Top Markets
Coin of the day
ReNeuron Group plc ReNeuron Group plc

ReNeuron Group plc

RENE
Rankning i aktier #41656
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc... Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
Aktiekurs
$0.00042815
Senast synkroniserad: 2024-02-27
Marknadsvärde
$13.55K
Förändring (1 dag)
0.03%
Förändring (1 år)
0.00%
Land
GB
Handel ReNeuron Group plc (RENE)

Kategori

EPS för ReNeuron Group plc (RENE)
EPS per 2026 TTM: 0
Enligt ReNeuron Group plcs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för ReNeuron Group plc från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter